Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company''s lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer''s disease (AD) and Parkinson''s disease, as well as is in clinical trials for Alzheimer''s disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Latest shares articles
Forex CFDs: Understanding currency forwards vs spot markets
Spot or forward? These two forex markets behave differently, and now you can trade both with us as forex CFDs. Here’s how they work, and what sets them apart.
15:01, 31 July 2025
Crypto CFDs: Popular cryptocurrencies for trading
Discover which cryptocurrencies are trending for CFD trading in 2025 – from bitcoin to newly listed coins like SUI and PEPE.
11:02, 31 July 2025
Ripple price prediction: Third-party price target
Ripple, launched in 2012 with the XRP Ledger, aims to make cross-border payments faster and cheaper using its native token, XRP. Backed by financial institutions and a strong market presence, it remains a major crypto asset by market cap.
14:39, 30 July 2025
Ethereum price prediction: Third-party price target
Your Ethereum price prediction resource for 2025 onward, with analyst outlooks, price targets and CFD trading strategies.
14:12, 30 July 2025
Ratings and Reviews
Ratings and Reviews
